Gene editor Scribe Therapeutics starts second-half IPO spree with $129M listing
Gene editor Scribe Therapeutics starts second-half IPO spree with $129M listing.
Scribe Therapeutics
Private
Scribe Therapeutics is a clinical-stage gene editing company developing next-generation CRISPR-based therapies for serious genetic diseases.
Company Info
Sector:Gene Therapy
Headquarters:San Diego, California, United States
Founded:2018
Website:www.scribetx.com/
Funding Round:Series C
Total Funding:>$200M
Funding & Investor Relations
Notable Investors
- ARCH Venture Partners
- Bayer
- Longevity Vision Fund
IPO Outlook / Plans
Filed S-1 July 2026
Upcoming Milestones & Key Dates
2026-Q3
Financial
IPO expected
Clinical Development Pipeline
SCR-101
Target: TTRSCR-201
Target: T cellsX-Edit platform
Target: CRISPR-based editingRecent News
Scribe records upsized $129M IPO to fund genetic med trials
Scribe records upsized $129M IPO to fund genetic med trials.
Early-stage Scribe wants to write IPO story even as investors favor derisked portfolios
Early-stage genetic medicines biotech Scribe Therapeutics signals IPO ambitions despite investor preference for de-risked late-stage assets. (Source: BioSpace, 2026-07-06)
Gene editing developer Scribe plots an IPO
Gene editing developer Scribe plots an IPO (BioPharma Dive.)
Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs — Endpoints News coverage of biopharma industry developments.
CRISPR Biotech Scribe Therapeutics Writes a New Chapter With $129M IPO
CRISPR Biotech Scribe Therapeutics Writes a New Chapter With $129M IPO.
Leadership Team
Gavin Jeffries
Chief Executive Officer
Dan Obringer
Chief Financial Officer
Catherine Stehman-Breen
Chief Medical Officer
Careers & Job Openings